Tumor gangliosides inhibit the tumor-specific immune response

Journal of Immunology

Volumn 163, Issue 7, 1999, Pages 3718-3726

  McKallip, Robert ^a   Li, Ruixiang ^a   Ladisch, Stephan ^a,b  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b CHILDREN S RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GANGLIOSIDE;

ANIMAL EXPERIMENT; ARTICLE; CANCER IMMUNOLOGY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ERYTHROLEUKEMIA; FEMALE; IMMUNIZATION; LYMPHOCYTE PROLIFERATION; MALIGNANT NEOPLASTIC DISEASE; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CELL DIVISION; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; G(M1) GANGLIOSIDE; GANGLIOSIDES; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA, ERYTHROBLASTIC, ACUTE; LYMPH NODES; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBSETS; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0033213878     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Burnet, F. M. 1970. The concept of immunological surveillance. Prog. Exp. Tumor Res. 13:1.
2. Bocchia, M., T. Korontsvit, Q. Xu, S. Mackinnon, S. Y. Yang, A. Sette, and D. A. Scheinberg. 1996. Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood 87:3587.
3. Cheever, M. A., M. L. Disis, H. Bernhard, J. R. Gralow, S. L. Hand, E. S. Huseby, H. L. Qin, M. Takahashi, and W. Chen. 1995. Immunity to oncogenic proteins. Immunol. Rev. 145:33.
4. Boon, T., and P. van der Bruggen. 1996. Human tumor antigens recognized by T lymphocytes. J. Exp. Med. 183:725.
5. Black, P. H. 1980. Shedding from the cell surface of normal and cancer cells. Adv. Cancer Res. 32:75.
6. Chen, Q., V. Daniel, D. W. Maher, and P. Hersey. 1994. Production of IL-10 by melanoma cells: examination of its role in immunosuppression mediated by melanoma. Int. J. Cancer 16:755.
7. Tada, T., S. Ohzeki, K. Utsumi, H. Takiuchi, M. Muramatsu, X. F. Li, J. Shimizu, H. Fujiwara, and T. Hamaoka. 1991. Transforming growth factor-β-induced inhibition of T cell function: susceptibility difference in T cells of various phenotypes and functions and its relevance to immunosuppression in the tumor-bearing state. J. Immunol. 146:1077.
8. Ladisch, S., B. Gillard, and C. Wong. 1983. Shedding and immunoregulatory activity of YAC-1 lymphoma cell gangliosides. Cancer Res. 43:3808.
9. Skipksi, V. P., N. Katopodis, J. S. Prendergast, and C. C. Stock. 1975. Gangliosides in blood serum of normal rats and Morris hepatoma 5123tc-bearing rats. Biochem. Biophys. Res. Commun. 67:1122.
10. Kloppel, T. M., T. W. Keenan, M. J. Freeman, and D. J. Morre. 1977. Glycolipidbound sialic acid in serum: increased levels in mice and humans bearing mammary carcinomas. Proc. Natl. Acad. Sci. USA 74:3011.
11. Ladisch, S., and Z.-L. Wu. 1985. Detection of a tumor-associated ganglioside in plasma of patients with neuroblastoma. Lancet 1:136.
12. Li, R., and S. Ladisch. 1991. Shedding of human neuroblastoma gangliosides. Biochim. Biophys. Acta 1083:57.
13. Ladisch, S., L. Ulsh, B. Gillard, and C. Wong. 1984. Modulation of the immune response by gangtiosides: inhibition of adherent monocyte accessory function in vitro. J. Clin. Invest. 74:2074.
14. Heitger, A., and S. Ladisch. 1996. Gangliosides block antigen presentation by human monocytes. Biochim. Biophy. Acta 1303:161.
15. Miller, H. C., and W. J. Esselman. 1975. Modulation of the immune response by antigen reactive lymphocytes after cultivation with gangliosides. J. Immunol. 115:839.
16. Lengle, E. E., R. Krishnaraj, and R. G. Kemp. 1979. Inhibition of the lectin-induced mitogenic response of thymocytes by. Cancer Res. 39:817.
17. Ryan, J., and M. Shinitzky. 1979. Possible role of glycosphingolipids in the control of immune responses. Eur. J. Immunol. 9:171.
18. Whisler, R., and A. Yates. 1980. Regulation of lymphocyte responses by human gangliosides. I. Characteristics of inhibitory effects and the induction of impaired activation. J. Immunol. 125:2106.
19. Lu, P., and F. J. Sharom. 1996. Immunosuppression by YAC-1 lymphoma: role of shed gangliosides. Cell. Immunol. 173:22.
20. Bergelson, L. D., E. V. Dyatlovitskaya, T. E. Klyuchareva, E. V. Kryukova, A. F. Lemenovskaya, V. A. Matveeva, and E. V. Sinitsyna. 1989. The role of glycosphingolipids in natural immunity: gangliosides modulate the cytotoxicity of natural killer cells. Eur. J. Immunol. 19:1979.
21. M2 on the K562 cell line is recognized as a target structure by human natural killer cells. Int. J. Cancer 40:12.
22. Grayson, G., and S. Ladisch. 1992. Immunosuppression by human gangliosides. II. Carbohydrate structure and inhibition of human NK activity. Cell. Immunol. 139:18.
23. Kern, D. E., J. P. Klarnet, M. C. Jensen, and P. D. Greenberg. 1986. Requirement for recognition of class II molecules and processed tumor antigens for optimal generation of syngeneic tumor-specific class I-restricted CTL. J. Immunol. 136: 4303.
24. Ladisch, S., and B. Gillard. 1985. A solvent partition method for microscale ganglioside purification. Anal. Biochem. 146:220.
25. Svennerholm, L. 1957. A colorimetric resorcinol-hydrochloric acid method. Biochim. Biophys. Acta 24:604.
26. Ledeen, R., and R. Yu. 1982. Gangliosides: structures, isolation and analysis. Methods Enzymol. 83:139.
27. Gazzotti, G., S. Sonnino, and R. Ghidoni. 1985. Normal-phase high-performance liquid chromatographic separation of non-derivatized ganglioside mixtures. J. Chromatogr. 348:371.
28. Li, R., D. Gage, and S. Ladisch. 1993. Biosynthesis and shedding of murine lymphoma gangliosides. Biochim. Biophys. Acta 1170:283.
29. Ladisch, S., S. Kitada, and E. F. Hays. 1987. Gangliosides shed by tumor cells enhance tumor formation in mice. J. din. Invest. 79:1879.
30. Kroczek, R. A., C. D. Black, J. Barbet, L. J. Edison, and E. M. Shevach. 1987. Induction of IL-2 receptor in vivo: response to allogeneic cells. Transplantation 44:547.
31. Li, R., N. Villacreses, and S. Ladisch. 1995. Human tumor gangliosides inhibit marine immune responses in vivo. Cancer Res. 55:211.
32. Morris, R. E., J. Wu, and R. Shorthouse. 1990. A study of the contrasting effects of cyclosporine, FK 506, and rapamycin on the suppression of allograft rejection. Transplant. Proc. 22:1638.
33. Ladisch, S., C. Sweeley, H. Becker, and D. Gage. 1989. Aberrant fatty acyl α-hydroxylation in human neuroblastoma tumor gangliosides. J. Biol. Chem. 264:12097.
34. Ladisch, S., R. Li, and E. Olson. 1994. Ceramide structure predicts tumor ganglioside immunosuppressive activity. Proc. Natl. Acad. Sci. USA 91:1974.
35. Chang, F., R. Li, K. Noon, D. Gage, and S Ladisch. 1997. Human medulloblastoma gangliosides. Glycobiology 7:523.
36. Ladisch, S., H. Becker, and L. Ulsh. 1992. Immunosuppression by human gangliosides. I. Relationship of carbohydrate structure to the inhibition of T cell responses. Biochim. Biophys. Acta 1125:180.
37. Tanaka, K., T. Yoshioka, C. Bieberich, and G. Jay. 1988. Role of the major histocompatibility complex class I antigens in tumor growth and metastasis. Anna. Rev. Immunol. 6:359.
38. Rogers, M. J., L. W. Law, E. Appella, S. Oroszlan, and C. C. Ting. 1977. Solubilized TSTA and the major viral structural proteins, gp70 and p30, in the immune response to murine leukemias induced by Friend and Rauscher virus. Int. J. Cancer 20:303.
39. Olshefski, R., and S. Ladisch. 1996. Intercellular transfer of shed tumor cell gangliosides. FEBS Lett. 386:11.
40. Olshefski, R., and S. Ladisch. 1998. Synthesis, shedding, and intercellular transfer of human medulloblastoma gangliosides: abrogation by a new inhibitor of glucosylceramide synthase. J. Neurochem. 70:467.
41. Floutsis, G., L. Ulsh, and S. Ladisch. 1989. Immunosuppressive activity of human neuroblastoma tumor gangliosides. Int. J. Cancer 43:6.
42. D2+ Glycoconj. J. 13:385.
43. Li, R., and S. Ladisch. 1996. Abrogation of shedding of immunosuppressive neuroblastoma gangliosides. Cancer Res. 56:4602.
44. Sharom, F. J., A. L. Chiu, and J. W. Chu. 1991. Membrane gangliosides modulate interleukin-2-stimulated T-lymphocyte proliferation. Biochim. Biophys. Acta 1094:35.
45. Offner, H., T. Thieme, and A. A. Vandenbark. 1987. Gangliosides induce selective modulation of CD4 from helper T lymphocytes. J. Immunol. 139:3295.
46. M3: involvement of serine phosphorylation and protein kinase Cδ translocation. J. Biol. Chem. 273:35153.
47. M1, ganglioside is regulated by phosphatases and kinases: evidence from enzyme inhibitors and anti-CD45 antibodies. Cell. Immunol. 187: 45.
48. Irani, D. N. 1998. Brain-derived gangliosides induce cell cycle arrest in a murine T cell line. J. Neuroimmmol. 87:11.
49. M3 induce interleukin-10 production by human T cells. Biockem. Biophys. Res. Commun. 256:41.
50. Valentino, L., T. Moss, E. Olson, H. J. Wang. R. Elashoff, and S. Ladisch. 1990. Shed tumor gangliosides and progression of human neuroblastoma. Blood 75: 1564.
51. Velders, M. P., H. Schreiber, and W. M. Kast. 1998. Active immunization against cancer cells: impediments and advances. Semin. Oncol. 25:697.
52. Dranoff, G. 1998. The use of gene transfer in cancer immunotherapy. Forum 8:357.
53. Simons, J. W., and B. Mikhak. 1998. Ex-vivo gene therapy using cytokine-transduced tumor vaccines: molecular and clinical pharmacology. Semin. Oncol. 25: 661.
54. Inokuchi, J., K. Momosaki, H. Shimeno, A. Nagamatsu, and N. S. Radin. 1989. Effects of D-threo-PDMP, an inhibitor of glucosylceramide synthetase, on expression of cell surface glycolipid antigen and binding to adhesive proteins by B16 melanoma cells. J. Cell Physiol. 141:573.
55. Abe, A., J. Inokuchi, M. Jimbo, H. Shimeno, A. Nagamatsu, J. A. Shayman, G. S. Shukla, and N. S. Radin. 1992. Improved inhibitors of glucosylceramide synthase. J. Biochem. 111:191.